全文获取类型
收费全文 | 824篇 |
免费 | 343篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 8篇 |
妇产科学 | 1篇 |
基础医学 | 174篇 |
口腔科学 | 51篇 |
临床医学 | 69篇 |
内科学 | 155篇 |
皮肤病学 | 22篇 |
神经病学 | 48篇 |
特种医学 | 5篇 |
外科学 | 82篇 |
综合类 | 59篇 |
预防医学 | 5篇 |
眼科学 | 5篇 |
药学 | 67篇 |
中国医学 | 51篇 |
肿瘤学 | 372篇 |
出版年
2024年 | 1篇 |
2023年 | 11篇 |
2022年 | 24篇 |
2021年 | 47篇 |
2020年 | 164篇 |
2019年 | 122篇 |
2018年 | 112篇 |
2017年 | 119篇 |
2016年 | 98篇 |
2015年 | 100篇 |
2014年 | 112篇 |
2013年 | 78篇 |
2012年 | 63篇 |
2011年 | 48篇 |
2010年 | 26篇 |
2009年 | 8篇 |
2008年 | 3篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2005年 | 2篇 |
2002年 | 1篇 |
1999年 | 1篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1985年 | 3篇 |
1983年 | 9篇 |
1982年 | 5篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1973年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有1181条查询结果,搜索用时 0 毫秒
1.
Long Wang Qun Zhang Pei Wu Wei Xiang Dan Xie Ning Wang Minhua Deng Ke Cao Hongliang Zeng Zhenzhou Xu Xiaoming Liu Leye He Zhi Long Jing Tan Jinrong Wang Bin Liu Jianye Liu 《Cancer science》2020,111(7):2349-2360
Solute carrier family 12 member 5 (SLC12A5) has an oncogenic role in bladder urothelial carcinoma. The present study aimed to characterize the molecular mechanisms of SLC12A5 in bladder urothelial carcinoma pathogenesis. Functional assays identified that in bladder urothelial carcinoma SLC12A5 interacts with and stabilizes SOX18, and then upregulates matrix metalloproteinase 7 (MMP7). In vivo and in vitro assays were performed to confirm the effect of SLC12A5’s interaction with SOX18 on MMP7‐mediated bladder urothelial carcinoma progression. SLC12A5 was upregulated in human bladder tumors, and correlated with the poor survival of patients with bladder urothelial carcinoma tumor invasion and metastasis, promoted by SLC12A5 overexpression. We demonstrated that SLC12A5 interacted with SOX18, and then upregulated MMP7, thus enhancing tumor progression. Importantly, SLC12A5 expression correlated positively with SOX18 and MMP7 expression in bladder urothelial carcinoma. Furthermore, SLC12A5 expression was suppressed by miR‐133a‐3p. Ectopic expression of SLC12A5 partly abolished miR‐133a‐3p‐mediated suppression of cell migration. SLC12A5‐SOX18 complex‐mediated upregulation on MMP7 was important in bladder urothelial carcinoma progression. The miR‐133a‐3p/SLC12A5/SOX18/MMP7 signaling axis was critical for progression, and provided an effective therapeutic approach against bladder urothelial carcinoma. 相似文献
2.
目的:探讨miR-204在人视网膜母细胞瘤中的表达、临床意义及其分子机制。方法:实时定量PCR检测miR-204在视网膜母细胞瘤及瘤旁组织中的表达并分析其与临床病理特征的关系。检测miR-204在视网膜母细胞瘤细胞系中的表达,并用miR-204模拟物转染Y79细胞,MTT及流式细胞仪检测Y79细胞的增殖、凋亡情况,RT-PCR、Western blot法检测Bcl-2 mRNA、蛋白的表达。结果:miR-204在视网膜母细胞瘤组织中的表达水平显著低于对应瘤旁组织。miR-204低表达与神经浸润、分化程度密切相关。miR-204可显著抑制Y79细胞的增殖并促进其凋亡,下调Bcl-2 mRNA及蛋白表达水平。结论:miR-204在人视网膜母细胞瘤组织中表达下调,并与临床病理相关,miR-204抑制Y79细胞增殖、促进凋亡的作用可能与下调Bcl-2有关。 相似文献
3.
Downregulation of microRNA‐100/microRNA‐125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion 下载免费PDF全文
Yasuteru Fujino Shunsaku Takeishi Kensei Nishida Koichi Okamoto Naoki Muguruma Tetsuo Kimura Shinji Kitamura Hiroshi Miyamoto Akiko Fujimoto Jun Higashijima Mitsuo Shimada Kazuhito Rokutan Tetsuji Takayama 《Cancer science》2017,108(3):390-397
A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR‐100 and miR‐125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real‐time PCR in a larger set of clinical samples. The transfection of a miR‐100 or miR‐125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR‐100 or miR‐125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR‐100‐silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real‐time PCR identified mammalian target of rapamycin (mTOR) and insulin‐like growth factor 1 receptor (IGF1R) as direct, and Fas and X‐linked inhibitor‐of‐apoptosis protein (XIAP) as indirect candidate targets for miR‐100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR‐100 and miR‐125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR‐100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR‐100 and miR‐125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion. 相似文献
4.
5.
6.
7.
At least half of all cancer patients will receive radiation therapy. Tumour radioresistance, or the failure to control certain tumours with this treatment, can result in locoregional recurrence; thus there is great interest in understanding the underlying biology and developing strategies to overcome this problem. The expanding investigation of microRNA in cancer suggests that these regulatory factors can influence the DNA damage response, the microenvironment and survival pathways, among other processes, and thereby may affect tumour radioresistance. As microRNA are readily detectable in tumours and biofluids, they hold promise as predictive biomarkers for therapy response and prognosis. This review highlights the current insights on the major ways that microRNA may contribute to tumour radiation response and whether their levels reflect treatment success. We conclude by applying the potential framework of future roles of miR in personalised radiotherapy using prostate cancer clinical management as an example. 相似文献
8.
《Expert review of anti-infective therapy》2013,11(3):359-362
miRNAs are short, nonprotein coding RNAs that regulate target gene expression principally by causing translational repression and/or mRNA degradation. miRNAs are involved in most mammalian biological processes and have pivotal roles in controlling the expression of factors involved in basal and stimulus-induced signaling pathways. Considering their central role in the regulation of gene expression, miRNAs represent therapeutic drug targets. Here we describe how miRNAs are involved in the regulation of aspects of innate immunity and inflammation, what happens when this goes awry, such as in the chronic inflammatory lung diseases cystic fibrosis and asthma, and discuss the current state-of-the-art miRNA-targeted therapeutics. 相似文献
9.
10.
J. Devon Roll Ashley G. Rivenbark Rupninder Sandhu Joel S. Parker Wendell D. Jones Lisa A. Carey Chad A. Livasy William B. Coleman 《Experimental and molecular pathology》2013
A subset of human breast cancer cell lines exhibits aberrant DNA hypermethylation that is characterized by hyperactivity of the DNA methyltransferase enzymes, overexpression of DNMT3b, and concurrent methylation-dependent silencing of numerous epigenetic biomarker genes. The objective of this study was to determine if this aberrant DNA hypermethylation (i) is found in primary breast cancers, (ii) is associated with specific breast cancer molecular subtypes, and (iii) influences patient outcomes. Analysis of epigenetic biomarker genes (CDH1, CEACAM6, CST6, ESR1, GNA11, MUC1, MYB, SCNN1A, and TFF3) identified a gene expression signature characterized by reduced expression levels or loss of expression among a cohort of primary breast cancers. The breast cancers that express this gene expression signature are enriched for triple-negative subtypes — basal-like and claudin-low breast cancers. Methylation analysis of primary breast cancers showed extensive promoter hypermethylation of epigenetic biomarker genes among triple-negative breast cancers, compared to other breast cancer subclasses where promoter hypermethylation events were less frequent. Furthermore, triple-negative breast cancers either did not express or expressed significantly reduced levels of protein corresponding to methylation-sensitive biomarker gene products. Together, these findings suggest strongly that loss of epigenetic biomarker gene expression is frequently associated with gene promoter hypermethylation events. We propose that aberrant DNA hypermethylation is a common characteristic of triple-negative breast cancers and may represent a fundamental biological property of basal-like and claudin-low breast cancers. Kaplan–Meier analysis of relapse-free survival revealed a survival disadvantage for patients with breast cancers that exhibit aberrant DNA hypermethylation. Identification of this distinguishing trait among triple-negative breast cancers forms the basis for development of new rational therapies that target the epigenome in patients with basal-like and claudin-low breast cancers. 相似文献